Browse > Article

Comparative study of therapeutic effects according to duration of medium-dose aspirin therapy at the acute stage of Kawasaki disease  

Lee, Jung Hwa (Department of Pediatrics, School of Medicine, Konkuk University)
Lee, So Hee (Department of Pediatrics, School of Medicine, Konkuk University)
Lee, Sang Taek (Department of Pediatrics, School of Medicine, Konkuk University)
Park, Yong Hyun (Department of Nursing, Chungju Hospital, Konkuk University)
Hong, Seong Jin (Department of Pediatrics, School of Medicine, Konkuk University)
Publication Information
Clinical and Experimental Pediatrics / v.49, no.7, 2006 , pp. 790-795 More about this Journal
Abstract
Purpose : This study was performed to compare the therapeutic effects according to duration of medium-dose aspirin(50-60 mg/kg/day) therapy at the acute stage of Kawasaki disease(KD). Methods : Total 87 patients with KD were enrolled in this study. We performed retrospective analysis of clinical characteristics and echocardiographic findings based on medical records. Patient were randomly divided into 2 groups according to the duration of aspirin therapy at the acute stage of KD. Long-term group(LG, n=55) was administered medium-dose aspirin for 2 weeks after diagnosis of KD, and short-term group(SG, n=32) for 48 hours after intravenous immunoglobulin(IVIG) administration. The parameters of therapeutic effects were duration of fever after IVIG administration, incidence of unresponsive patients to single administration of IVIG, and development of transient dilatation or aneurysm of coronary arteries. Results : There was no significant difference in the duration of fever after IVIG between the both group(LG $1.7{\pm}1.1$ days, SG $1.8{\pm}1.1$ days; P=0.588). The incidences of unresponsive patient to the single administration of IVIG were 5.5 percent, 6.3 percent in the each group. Transient dilatation of coronary arteries occurred at 18.2 percent(10/55) in the LG, and 15.6 percent(5/32) in the SG(P=0.761). Prevalence of coronary aneurysm after subacute stage were 7.3 percent(4/55) in the LG, and 9.4 percent(3/32) in the SG(P=0.728). Conclusion : There was no significant difference in the therapeutic effects between long-term(2 weeks) and short-term(48 hours) administration of medium-dose aspirin at the acute stage of KD.
Keywords
Kawasaki disease; Aspirin; Therapeutic effects;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and longterm management of Kawasaki disease : A statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, Council on cardiovascular disease in the young, American Heart Association. Circulation 2004;110:2747-71   DOI   ScienceOn
2 Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan. Ministry of Health and Welfare. 1984
3 Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y Kazue T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85   DOI   ScienceOn
4 Koren G, Rose V, Lavi S, Rowe R. Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA 1985;254:767-9   DOI
5 Ichida F, Fatica NS, Engle MA, O'Loughlin JE, Klein AA, Snyder MS, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York : risk factors and role of aspirin. Pediatrics 1987;80:828-35
6 Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin but independent of salicylate dose. J Pediatr 1997;131:888-93   DOI   ScienceOn
7 Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr 2002;41:597-601   DOI
8 Matsubara T, Mason W, Kashini IA. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 1996;128:701-3   DOI   ScienceOn
9 Kato H, Koike S, Yokoyama T. Kawasaki disease : effect of treatment on coronary artery involvement. Pediatrics 1979; 63:175-9
10 Lee JH, Hung HY, Huang FY. Kawasaki disease and Reye syndrome : report of one case. Acta Paed Sin 1992;33:67-71
11 Akagi T, Kato H, Inoue O, Sato N. Salicylate treatment in Kawasaki disease : High dose or low dose? Eur J Pediatr 1991;150:642-6   DOI
12 Melish ME. Comparison of low-dose aspirin vs. high dose aspirin as an adjunct to intravenous gamma globulin in the treatment of Kawasaki syndrome. Pediatr Res 1992;31:170A   DOI   ScienceOn
13 Furusho K, Sato K, Soeda T, Matsumoto H, Hirota T, Kawada S. High-dose intraveous gammaglobulin for Kawasaki disease. Lancet 1983;10:1359
14 Hanley SP, Bevan J, Cockbill SR, Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1981;2:969-71
15 Kusakawa S, Tatara K. Efficacies and risks of aspirin in the treatment of Kawasaki disease. Prog Clin Biol Resear 1987;250:401-13
16 Jacobs JC. Successful treatment of Kawasaki disease with high dose aspirin. Pediatr Res 1978;12:494
17 Harada K. Intravenous gammaglobulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10   DOI
18 Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Haung SM. Treatment of acute Kawasaki disease : Aspirin's role in the febrile stage revisited. Pediatrics 2004;114:689-93   DOI   ScienceOn
19 Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease : a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61
20 Koren G, Schaffer F, Silverman E. Determinant of low serum concentrations of salicylate in patient with Kawasaki disease. J Pediatr 1988;112:663-7   DOI
21 Mulberg AE, Verhave M. Identification and treatment of nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Am J Dis Child 1993;147:1280-1
22 Shulman ST, Rowley SH. Advances in Kawasaki disease. Eur J Pediatr 2004;163:285-91   DOI   ScienceOn
23 Moran AM, Newburger JW, Sanders SP, Parness IA, Spevak PJ, Burns JC, et al. Abnormal myocardial mechanics in Kawasaki disease : rapid response to gamma-globulin. Am Heart J 2000;139:217-23